文献速递系统性红斑狼疮

在幼年起病系统性红斑狼疮年轻患者中,可用新型脂质代谢组学特征预测APPLE试验中的动脉粥样硬化进展

Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.
PubMed 文献 · Arthritis Rheumatol · 2023-12-19

本研究基于APPLE试验(阿托伐他汀与安慰剂对照,以颈动脉内膜中层厚度CIMT为主要结局),对151例幼年起病系统性红斑狼疮(JSLE)患者按基线CIMT及36个月CIMT进展进行无监督聚类,分为高、中、低CIMT轨迹三组。安慰剂组(n=60)中高CIMT进展者总胆固醇(P=0.001)和低密度脂蛋白(LDL)胆固醇(P=0.002)较高但均在参考范围内,并识别出预测高CIMT进展的基线代谢组学特征(曲线下面积80.7%)。阿托伐他汀组(n=61)36个月后LDL胆固醇降低,但仍有36%患者动脉粥样硬化高进展,且不能被代谢组学生物标志物预测。

要点

  • 基线CIMT可将JSLE患者分为高、中、低CIMT轨迹三组,与治疗分配无关。
  • 安慰剂组中高CIMT进展者总胆固醇(P=0.001)和LDL胆固醇(P=0.002)较高但均在参考范围内。
  • 基线代谢组学特征可预测安慰剂组高CIMT进展,曲线下面积80.7%。

核心结论

  • JSLE存在显著的基线异质性和不同的亚临床动脉粥样硬化进展轨迹。
  • 代谢组学特征可预测部分JSLE患者的动脉粥样硬化进展,与临床试验分层相关。

研究设计与样本

  • 基于APPLE试验(阿托伐他汀与安慰剂对照,以CIMT为主要结局的随机对照试验)的分析。
  • 对基线CIMT及36个月CIMT进展进行无监督聚类以分层JSLE患者,并分析疾病特征、心血管风险评分和基线血清代谢组。
  • 采用机器学习技术识别并验证CIMT进展的血清代谢组学特征。

主要发现

  • 基线CIMT将151例JSLE患者分为高、中、低CIMT轨迹三组,与治疗分配无关。
  • 多数患者按推荐评估标准的心血管疾病风险低。
  • 安慰剂组(n=60)中高CIMT进展者总胆固醇较高(P=0.001)且LDL胆固醇较高(P=0.002),但均在参考范围内。
  • 安慰剂组中识别出预测高CIMT进展的稳健基线代谢组学特征,曲线下面积80.7%。
  • 阿托伐他汀组(n=61)36个月后LDL胆固醇降低,但36%仍有高动脉粥样硬化进展,且不能被代谢组学生物标志物预测。

关键数值与推荐

  • 高CIMT进展者总胆固醇P=0.001、LDL胆固醇P=0.002(均较低于低CIMT进展者,但原文未报告具体数值)。
  • 预测高CIMT进展的代谢组学特征曲线下面积80.7%。
  • 阿托伐他汀组36个月后LDL胆固醇降低,但36%仍有高动脉粥样硬化进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with juvenile-onset systemic lupus erythematosus (JSLE) have increased atherosclerosis risk. This study investigated novel atherosclerosis progression biomarkers in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, the largest investigator-led randomized control trial of atorvastatin versus placebo for atherosclerosis progression in JSLE, using carotid intima-media thickness (CIMT) as the primary outcome. METHODS: Unsupervised clustering of baseline CIMT and CIMT progression over 36 months was used to stratify patients with JSLE. Disease characteristics, cardiovascular risk scores, and baseline serum metabolome were investigated in CIMT-stratified patients. Machine learning techniques were used to identify and validate a serum metabolomic signature of CIMT progression. RESULTS: Baseline CIMT stratified patients with JSLE (N = 151) into three groups with distinct high, intermediate, and low CIMT trajectories irrespective of treatment allocation, despite most patients having low cardiovascular disease risk based on recommended assessment criteria. In the placebo group (n = 60), patients with high versus low CIMT progression had higher total (P = 0.001) and low-density lipoprotein (LDL) (P = 0.002) cholesterol levels, although within the reference range. Furthermore, a robust baseline metabolomic signature predictive of high CIMT progression was identified in the placebo arm (area under the curve, 80.7%). Patients treated with atorvastatin (n = 61) had reduced LDL cholesterol levels after 36 months, as expected; however, despite this, 36% still had high atherosclerosis progression, which was not predicted by metabolomic biomarkers, suggesting nonlipid drivers of atherosclerosis in JSLE with management implications for this subset of patients. CONCLUSION: Significant baseline heterogeneity and distinct subclinical atherosclerosis progression trajectories exist in JSLE. Metabolomic signatures can predict atherosclerosis progression in some patients with JSLE with relevance for clinical trial stratification.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Peng J, Dönnes P, Ardoin SP, et al. Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis Rheumatol. 2023. PMID: 37786302. doi:10.1002/art.42722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。